Your browser doesn't support javascript.
loading
Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma.
Kong, Xiaoshuang; Zhang, Xudong; Ding, Mengjie; Feng, Xiaoyan; Dong, Meng; Zhang, Lei; Fu, Xiaorui; Li, Ling; Li, Xin; Sun, Zhenchang; Yan, Jiaqin; Wang, Xinhua; Wu, Xiaolong; Chen, Qingjiang; Zhang, Mingzhi; Zhu, Linan.
Affiliation
  • Kong X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Zhang X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Ding M; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Feng X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Dong M; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Zhang L; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Fu X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Li L; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Li X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Sun Z; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Yan J; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Wang X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Wu X; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Chen Q; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Zhang M; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Zhu L; Department of Oncology, Lymphoma Diagnosis and Treatment Centre of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Cancer Med ; 12(7): 8134-8143, 2023 04.
Article in En | MEDLINE | ID: mdl-36695162
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: China Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: China Country of publication: United States